41:I[185,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SendEmailButton"] 43:I[63625,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"AddToLibraryButton"] 44:I[29721,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ShareButton"] 45:I[58016,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ProcessEpisodeButton"] 46:I[45269,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SignupCTA"] 3a:["$","h1",null,{"className":"max-w-[22ch] font-display text-[clamp(32px,4.5vw,48px)] font-medium leading-[1.05] tracking-[-0.02em] text-[color:var(--fg-1)] text-balance","children":"Episode 2: The Impact of Semaglutide or Ozempic on Weight Loss and Health"}] 3b:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2024-03-09T12:06:37.000Z","children":"March 9, 2024"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:04:25"}],false]}] 42:T549,

This episode of 'Living Diabetes' delves into Semaglutide, a GLP-1 agonist marketed under names such as Wegovy and Ozempic, renowned for its weight loss benefits and management of type 2 diabetes. Initially approved by the FDA in 2005, GLP-1 agonists have evolved, with Semaglutide offering a convenient weekly injection. The drug induces weight loss by promoting satiety, decreasing food intake, and influencing eating habits. However, it also triggers nausea and vomiting in some individuals. While effective, discontinuation often leads to significant weight regain, highlighting the necessity of combining Semaglutide with lasting dietary and lifestyle changes. Recent studies have indicated potential risks like pancreatitis, kidney failure, and muscle mass decrease, underscoring the importance of medical supervision and proactive health management.

00:00 Introduction to Semaglutide: A Revolutionary Weight Loss Medication

00:08 Understanding Semaglutide: From Development to Weight Loss Mechanisms

01:44 The Multifaceted Impact of Semaglutide on Weight Management

02:05 Challenges and Considerations in Using Semaglutide

02:49 Combating the "Ozempic Rebound": Strategies for Sustainable Weight Loss

03:23 Preserving Muscle Mass While on Ozempic

03:57 Final Thoughts and Recommendation